Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Epratuzumab: Phase II

Preliminary data from 44 patients in IMMU's ongoing 70-patient U.S. Phase

Read the full 112 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE